{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:10:49Z","timestamp":1781179849908,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2012028833"],"award-info":[{"award-number":["2012028833"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2010-0027955"],"award-info":[{"award-number":["2010-0027955"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jconrel.2017.01.020","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T14:16:54Z","timestamp":1484576214000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Metronomic chemotherapy using orally active carboplatin\/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management"],"prefix":"10.1016","volume":"249","author":[{"given":"Foyez","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Uk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Who","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-San","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.01.020_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0020","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0025","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.addr.2012.11.005","article-title":"Pharmaceutical nanotechnology for oral delivery of anticancer drugs","volume":"65","author":"Mei","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral delivery of anticancer drugs: challenges and opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2015.90","article-title":"Refining the treatment of NSCLC according to histological and molecular subtypes","volume":"12","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-015-1354-2","article-title":"Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)","volume":"15","author":"Camerini","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4161\/cbt.12.2.15722","article-title":"Phase II trial of bevacizumab and dose\/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients","volume":"12","author":"Correale","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154316","article-title":"Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules","volume":"11","author":"Sutiman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12967-016-0812-1","article-title":"A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice","volume":"14","author":"Tagliamonte","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0085","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1038\/sj.onc.1206957","article-title":"Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents","volume":"22","author":"Gridelli","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/cgt.2012.18","article-title":"Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1","volume":"19","author":"Ou","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0100","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1172\/JCI65425","article-title":"ATP11B mediates platinum resistance in ovarian cancer","volume":"123","author":"Moreno-Smith","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0105","first-page":"1972","article-title":"Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA","volume":"46","author":"Knox","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target","volume":"3","author":"Balakrishnan","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0115","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1161\/hc5001.100627","article-title":"Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0120","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1038\/srep04163","article-title":"Functional transformations of bile acid transporters induced by high-affinity macromolecules","volume":"4","author":"Al-Hilal","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00125-004-1658-2","article-title":"A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine","volume":"48","author":"Lee","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0130","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11095-012-0932-0","article-title":"Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates","volume":"30","author":"Jeon","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0135","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/mp500626a","article-title":"Absorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestine","volume":"12","author":"Mahmud","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0140","first-page":"3049","article-title":"Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin","volume":"6","author":"Sun","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0145","series-title":"Comparative Anatomy and Histology","first-page":"229","article-title":"Urinary system","author":"Treuting","year":"2012"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00418-009-0577-1","article-title":"Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis","volume":"131","author":"Baratta","year":"2009","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0155","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0160","first-page":"7501","article-title":"Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo","volume":"61","author":"Bello","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0170","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1470-2045(14)70402-4","article-title":"Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data","volume":"15","author":"Rossi","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0175","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0022-3565(24)37216-7","article-title":"Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells","volume":"284","author":"Lindmark","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0185","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/js960529n","article-title":"Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy","volume":"86","author":"Sakai","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0190","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1158\/1078-0432.CCR-08-0606","article-title":"ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel\/carboplatin chemotherapy","volume":"14","author":"Johnatty","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(24)39291-2","article-title":"Expression and localization of multidrug resistant protein mrp2 in rat small intestine","volume":"293","author":"Mottino","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6603383","article-title":"Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer","volume":"95","author":"von Plessen","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0210","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2017.01.020_bb0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrc2791","article-title":"Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors","volume":"10","author":"Butler","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drudis.2012.08.004","article-title":"Oral delivery of anticancer drugs I: general considerations","volume":"18","author":"Mazzaferro","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0230","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jinorgbio.2007.03.017","article-title":"The activation of platinum(II) antiproliferative drugs in carbonate medium evaluated by means of a DNA-biosensor","volume":"101","author":"Ravera","year":"2007","journal-title":"J. Inorg. Biochem."},{"issue":"Suppl. 4","key":"10.1016\/j.jconrel.2017.01.020_bb0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-200059004-00003","article-title":"Clinical pharmacokinetics and administration of established platinum drugs","volume":"59","author":"O'Dwyer","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2017.01.020_bb0240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916306083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916306083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:28:26Z","timestamp":1749911306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916306083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":48,"alternative-id":["S0168365916306083"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.01.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronomic chemotherapy using orally active carboplatin\/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}